NASDAQ:SAGE - Sage Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $78.00
  • Forecasted Upside: 88.27 %
  • Number of Analysts: 19
  • Breakdown:
  • 0 Sell Ratings
  • 11 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$41.43
▲ +0.01 (0.02%)

This chart shows the closing price for SAGE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sage Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SAGE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SAGE

Analyst Price Target is $78.00
▲ +88.27% Upside Potential
This price target is based on 19 analysts offering 12 month price targets for Sage Therapeutics in the last 3 months. The average price target is $78.00, with a high forecast of $100.00 and a low forecast of $50.00. The average price target represents a 88.27% upside from the last price of $41.43.

This chart shows the closing price for SAGE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 19 investment analysts is to hold stock in Sage Therapeutics. This rating has held steady since December 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 10 hold ratings
  • 0 sell ratings
5/3/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 9 hold ratings
  • 0 sell ratings
8/1/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 10 hold ratings
  • 0 sell ratings
10/30/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 12 hold ratings
  • 0 sell ratings
1/28/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 10 hold ratings
  • 0 sell ratings
4/28/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 10 hold ratings
  • 0 sell ratings
7/27/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 10 hold ratings
  • 0 sell ratings
9/25/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 11 hold ratings
  • 0 sell ratings
10/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 11 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/20/2021Needham & Company LLCInitiated CoverageBuy$84.00 ➝ $80.00Low
10/20/2021OppenheimerLower Price TargetPositive ➝ Outperform$100.00 ➝ $84.00Low
10/18/2021SVB LeerinkReiterated RatingMarket PerformHigh
10/12/2021Morgan StanleyLower Price TargetEqual Weight$81.00 ➝ $78.00Low
10/7/2021SVB LeerinkReiterated RatingHoldLow
10/6/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$100.00 ➝ $50.00High
10/4/2021Stifel NicolausLower Price TargetBuy$95.00 ➝ $75.00High
9/22/2021Needham & Company LLCInitiated CoverageBuy$84.00High
8/4/2021Royal Bank of CanadaLower Price TargetSector Perform$60.00 ➝ $55.00Medium
8/4/2021HC WainwrightLower Price TargetNeutral$86.00 ➝ $80.00Medium
7/27/2021Canaccord GenuityLower Price TargetBuy$119.00 ➝ $96.00High
6/16/2021SVB LeerinkLower Price TargetMarket Perform$90.00 ➝ $70.00High
6/16/2021HC WainwrightReiterated RatingHoldHigh
6/16/2021Stifel NicolausLower Price TargetBuy$121.00 ➝ $95.00High
6/16/2021William BlairDowngradeOutperform ➝ Market Perform$62.00High
6/16/2021BMO Capital MarketsLower Price TargetPositive ➝ Market Perform$87.00 ➝ $73.00High
6/16/2021CitigroupDowngradeBuy ➝ Neutral$101.00 ➝ $68.00High
5/5/2021MizuhoLower Price TargetNeutral$81.00 ➝ $77.00Medium
4/19/2021Morgan StanleyLower Price TargetEqual Weight$87.00 ➝ $81.00Low
4/12/2021MizuhoReiterated RatingHold$81.00High
4/7/2021Piper SandlerInitiated CoverageOverweight$100.00Medium
3/4/2021MizuhoReiterated RatingBuy ➝ Neutral$81.00High
3/2/2021Morgan StanleyBoost Price TargetEqual Weight$83.00 ➝ $87.00High
2/26/2021MizuhoDowngradeBuy ➝ Neutral$81.00High
2/25/2021OppenheimerBoost Price TargetOutperform$90.00 ➝ $102.00Low
2/25/2021HC WainwrightBoost Price TargetNeutral$74.00 ➝ $86.00High
2/25/2021HC WainwrightReiterated RatingNeutral$74.00 ➝ $86.00High
2/1/2021Raymond JamesInitiated CoverageMarket PerformLow
1/22/2021BMO Capital MarketsDowngradeOutperform ➝ Market Perform$95.00High
1/19/2021WedbushBoost Price TargetOutperform$83.00 ➝ $98.00Low
1/4/2021GuggenheimUpgradeNeutral ➝ BuyN/A
1/4/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$83.00 ➝ $86.00N/A
12/4/2020William BlairReiterated RatingBuyLow
12/4/2020MizuhoUpgradeNeutral ➝ Buy$77.00 ➝ $81.00Low
12/1/2020TruistBoost Price Target$60.00 ➝ $70.00Low
12/1/2020Smith Barney CitigroupLower Price Target$100.00 ➝ $93.00Low
12/1/2020Royal Bank of CanadaLower Price Target$86.00 ➝ $83.00Low
12/1/2020HC WainwrightLower Price TargetNeutral$81.00 ➝ $74.00Low
12/1/2020Morgan StanleyLower Price TargetEqual Weight$85.00 ➝ $83.00Low
11/30/2020Raymond JamesDowngradeOutperform ➝ Market PerformLow
11/19/2020OppenheimerBoost Price Target$65.00 ➝ $94.00Medium
11/16/2020Bank of AmericaBoost Price TargetBuy$72.00 ➝ $95.00High
11/16/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$87.00 ➝ $85.00High
11/10/2020TruistBoost Price TargetHold$35.00 ➝ $60.00Low
11/6/2020Smith Barney CitigroupBoost Price Target$67.00 ➝ $100.00Low
11/6/2020Canaccord GenuityBoost Price TargetBuy$82.00 ➝ $135.00Low
11/6/2020MizuhoBoost Price TargetNeutral$53.00 ➝ $77.00Medium
11/6/2020BMO Capital MarketsBoost Price TargetOutperform$79.00 ➝ $89.00Medium
11/6/2020HC WainwrightBoost Price TargetNeutral$76.00 ➝ $81.00Medium
10/20/2020Royal Bank of CanadaBoost Price TargetOutperform$75.00 ➝ $84.00Low
10/16/2020BMO Capital MarketsBoost Price TargetPositive ➝ Outperform$65.00 ➝ $79.00High
9/11/2020CitigroupBoost Price TargetPositive ➝ Buy$54.00 ➝ $67.00Low
9/11/2020WedbushUpgradeNeutral ➝ Outperform$40.00 ➝ $65.00Low
8/24/2020Morgan StanleyBoost Price TargetOverweight$85.00 ➝ $87.00Medium
8/11/2020Royal Bank of CanadaReiterated RatingBuyMedium
8/11/2020OppenheimerBoost Price TargetOutperform$50.00 ➝ $65.00High
8/10/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$70.00Low
8/10/2020MizuhoReiterated RatingHold$44.00High
5/26/2020Royal Bank of CanadaBoost Price TargetOutperform$72.00 ➝ $75.00Low
5/8/2020SunTrust BanksLower Price TargetHold$37.00 ➝ $35.00High
5/8/2020Royal Bank of CanadaBoost Price TargetOutperform$71.00 ➝ $72.00High
5/8/2020WedbushDowngradeOutperform ➝ Neutral$36.00 ➝ $37.00Medium
5/8/2020MizuhoBoost Price TargetNeutral$36.00 ➝ $44.00Medium
4/28/2020Royal Bank of CanadaBoost Price TargetOutperform$68.00 ➝ $71.00High
4/19/2020GuggenheimDowngradeBuy ➝ NeutralHigh
4/9/2020BMO Capital MarketsLower Price TargetOutperform$86.00 ➝ $65.00Medium
4/9/2020SunTrust BanksLower Price TargetHold$40.00 ➝ $37.00Medium
4/8/2020Canaccord GenuityLower Price TargetBuy$96.00 ➝ $80.00Low
4/8/2020Royal Bank of CanadaBoost Price TargetOutperform$60.00 ➝ $68.00High
4/8/2020WedbushLower Price TargetOutperform$56.00 ➝ $36.00High
4/8/2020OppenheimerLower Price TargetOutperform$60.00 ➝ $50.00High
4/8/2020CitigroupBoost Price TargetBuy$48.00 ➝ $54.00High
4/8/2020GuggenheimDowngradeBuy ➝ NeutralHigh
4/8/2020MizuhoLower Price TargetNeutral$58.00 ➝ $36.00High
3/26/2020SunTrust BanksLower Price TargetHold$50.00 ➝ $40.00Medium
3/22/2020HC WainwrightReiterated RatingHold$78.00Low
3/20/2020LADENBURG THALM/SH SHReiterated RatingHold$28.00High
3/19/2020OppenheimerLower Price Target$97.00 ➝ $60.00Low
3/19/2020SVB LeerinkBoost Price TargetMarket Perform$45.00 ➝ $63.00Low
3/19/2020GuggenheimLower Price TargetBuy$85.00 ➝ $65.00Low
3/19/2020CitigroupLower Price TargetBuy$71.00 ➝ $48.00Low
3/18/2020Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$73.00 ➝ $60.00High
3/11/2020MizuhoReiterated RatingHold$58.00High
3/5/2020CitigroupInitiated CoverageBuy$71.00High
3/3/2020Morgan StanleyLower Price TargetOverweight$125.00 ➝ $117.00Medium
2/28/2020SunTrust BanksLower Price TargetHold$60.00 ➝ $50.00High
2/28/2020LADENBURG THALM/SH SHReiterated RatingHold$52.00High
2/28/2020HC WainwrightLower Price TargetNeutral$87.00 ➝ $78.00High
2/28/2020MizuhoLower Price TargetNeutral$69.00 ➝ $58.00High
2/27/2020CowenReiterated RatingBuy$96.00High
2/27/2020MizuhoReiterated RatingHold$69.00High
2/5/2020MizuhoInitiated CoverageNeutral$69.00Low
1/7/2020Bank of AmericaBoost Price Target$85.00 ➝ $98.00Medium
12/6/2019OppenheimerLower Price Target$190.00 ➝ $100.00Medium
12/6/2019JPMorgan Chase & Co.Lower Price TargetOverweight$200.00 ➝ $105.00Low
12/6/2019LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralLow
12/6/2019Royal Bank of CanadaLower Price TargetOutperform$190.00 ➝ $100.00High
12/6/2019Morgan StanleyLower Price TargetOverweight$217.00 ➝ $125.00High
12/6/2019BMO Capital MarketsReiterated RatingOutperform$92.00High
12/6/2019SVB LeerinkUpgradeUnderperform ➝ Market PerformHigh
12/6/2019HC WainwrightLower Price TargetNeutral$160.00 ➝ $87.00High
12/5/2019The Goldman Sachs GroupLower Price Target$227.00 ➝ $263.00High
12/5/2019Piper Jaffray CompaniesLower Price TargetOverweight$206.00 ➝ $125.00High
12/5/2019GuggenheimLower Price TargetBuy$200.00 ➝ $110.00High
12/5/2019CowenReiterated RatingBuy$96.00High
12/5/2019Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$73.00High
12/5/2019WedbushLower Price TargetOutperform$203.00 ➝ $90.00High
12/5/2019SunTrust BanksDowngradeBuy ➝ Hold$210.00 ➝ $70.00High
11/25/2019Royal Bank of CanadaReiterated RatingBuy$235.00Low
11/24/2019Morgan StanleyReiterated RatingBuy$217.00Medium
11/20/2019Stifel NicolausReiterated RatingBuyLow
10/30/2019HC WainwrightInitiated CoverageNeutral$160.00Low
8/7/2019OppenheimerLower Price TargetOutperform$200.00 ➝ $190.00Medium
7/25/2019OppenheimerBoost Price Target$170.00 ➝ $200.00Medium
7/24/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
7/24/2019William BlairReiterated RatingBuyLow
5/22/2019WedbushInitiated CoverageOutperform ➝ Outperform$207.00Low
5/5/2019OppenheimerSet Price TargetBuy$170.00Medium
5/2/2019LADENBURG THALM/SH SHSet Price TargetBuy$220.00Low
4/26/2019Raymond JamesReiterated RatingMarket PerformMedium
4/25/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$195.00Low
4/8/2019Canaccord GenuitySet Price TargetBuy$220.00Low
2/22/2019GuggenheimInitiated CoverageBuy$205.00High
12/19/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$230.00 ➝ $213.00High
12/14/2018Wolfe ResearchInitiated CoverageOutperform ➝ OutperformMedium
12/11/2018LADENBURG THALM/SH SHSet Price TargetBuy$210.00High
11/20/2018OppenheimerSet Price TargetBuy$170.00Low
11/12/2018SVB LeerinkInitiated CoverageUnderperform$80.00High
11/6/2018JPMorgan Chase & Co.Set Price TargetBuy$205.00Medium
11/5/2018Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$259.00 ➝ $261.00Medium
11/4/2018OppenheimerSet Price TargetBuy$170.00High
11/1/2018Canaccord GenuitySet Price TargetBuy$220.00High
11/1/2018CowenReiterated RatingBuy$207.00High
10/31/2018LADENBURG THALM/SH SHSet Price TargetBuy$235.00High
10/29/2018OppenheimerSet Price TargetBuy$170.00High
10/17/2018OppenheimerInitiated CoverageBuy$170.00Medium
10/11/2018Morgan StanleyBoost Price TargetOverweight$228.00 ➝ $230.00High
10/10/2018OppenheimerInitiated CoverageBuy$170.00Low
8/8/2018Canaccord GenuitySet Price TargetBuy$220.00Low
8/7/2018Stifel NicolausBoost Price TargetBuy$198.00 ➝ $239.00Medium
8/6/2018Piper Jaffray CompaniesInitiated CoverageOverweight$206.00Medium
7/13/2018Morgan StanleyBoost Price TargetOverweight$225.00 ➝ $228.00Low
6/14/2018CowenReiterated RatingBuy$207.00Medium
6/12/2018Canaccord GenuityReiterated RatingBuy ➝ Buy$220.00High
6/6/2018LADENBURG THALM/SH SHInitiated CoverageBuy$230.00High
5/3/2018Canaccord GenuityReiterated RatingBuy$210.00Low
5/3/2018CowenReiterated RatingBuyLow
3/26/2018Canaccord GenuityReiterated RatingBuy ➝ Buy$210.00High
3/20/2018CowenReiterated RatingBuy$202.00Low
2/28/2018SunTrust BanksBoost Price TargetBuy$203.00Low
2/26/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$225.00Low
2/23/2018Needham & Company LLCReiterated RatingBuy$193.00Low
1/10/2018JPMorgan Chase & Co.Reiterated RatingBuyHigh
12/11/2017CowenReiterated RatingBuyLow
12/8/2017Stifel NicolausReiterated RatingBuy$198.00Low
12/8/2017SunTrust BanksBoost Price TargetPositive$178.00High
12/8/2017JPMorgan Chase & Co.Reiterated RatingOverweight$198.00High
12/7/2017Raymond JamesReiterated RatingBuy$206.00High
12/7/2017Canaccord GenuitySet Price TargetBuy ➝ Buy$140.00 ➝ $191.00High
12/7/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$100.00 ➝ $193.00High
12/7/2017SVB LeerinkBoost Price Target$123.00 ➝ $246.00High
12/7/2017BMO Capital MarketsReiterated RatingOutperform$203.00High
12/7/2017Royal Bank of CanadaBoost Price TargetOutperform ➝ Sell$137.00 ➝ $280.00High
11/27/2017Royal Bank of CanadaLower Price TargetOutperform$145.00 ➝ $137.00Medium
11/17/2017BMO Capital MarketsReiterated RatingOutperform$85.67 ➝ $112.00N/A
11/16/2017Bank of AmericaLower Price TargetBuy$103.00 ➝ $101.00N/A
11/15/2017SunTrust BanksBoost Price TargetBuy ➝ Positive$116.00N/A
11/10/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$86.00 ➝ $100.00N/A
11/10/2017Chardan CapitalUpgradeNeutral ➝ Buy$60.00 ➝ $140.00N/A
11/9/2017Raymond JamesBoost Price TargetBuy$109.00N/A
11/9/2017Stifel NicolausBoost Price TargetBuy$91.00 ➝ $105.00N/A
11/9/2017Royal Bank of CanadaBoost Price TargetOutperform$145.00N/A
11/9/2017SVB LeerinkBoost Price TargetOutperform ➝ Positive$85.00 ➝ $123.00N/A
11/2/2017Royal Bank of CanadaBoost Price Target$117.00 ➝ $120.00N/A
10/27/2017BMO Capital MarketsReiterated RatingBuy$80.00N/A
10/19/2017SunTrust BanksSet Price TargetBuy$82.00N/A
10/18/2017Royal Bank of CanadaReiterated RatingBuy$117.00N/A
10/6/2017The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$87.00N/A
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$117.00Medium
9/14/2017BMO Capital MarketsBoost Price TargetOutperform$80.00 ➝ $84.00High
9/13/2017Chardan CapitalReiterated RatingHoldHigh
9/13/2017Needham & Company LLCLower Price TargetBuy ➝ Buy$95.00 ➝ $86.00High
9/13/2017Stifel NicolausReiterated RatingBuy$104.00 ➝ $91.00High
9/13/2017SunTrust BanksReiterated RatingBuy$95.00 ➝ $82.00High
9/12/2017Canaccord GenuityLower Price TargetBuy$110.00 ➝ $81.00High
9/12/2017JPMorgan Chase & Co.Lower Price TargetOverweight$99.00 ➝ $85.00High
9/12/2017CowenLower Price TargetOutperform$100.00 ➝ $90.00Medium
8/31/2017JPMorgan Chase & Co.Reiterated RatingBuyLow
8/9/2017Stifel NicolausInitiated CoverageBuy$104.00Low
8/5/2017Canaccord GenuitySet Price TargetBuy$110.00Medium
8/4/2017CowenReiterated RatingBuy$100.00Medium
8/4/2017Needham & Company LLCSet Price TargetBuy$82.00 ➝ $95.00High
8/4/2017HC WainwrightBoost Price TargetNeutral$86.00High
7/28/2017BMO Capital MarketsReiterated RatingBuy$82.00Medium
7/14/2017Stifel NicolausReiterated RatingBuy$90.00Medium
6/20/2017SVB LeerinkReiterated RatingOutperform$90.00 ➝ $97.00High
6/13/2017Needham & Company LLCReiterated RatingBuy$82.00Medium
6/12/2017CowenInitiated CoverageOutperform$95.00Low
5/15/2017Needham & Company LLCInitiated CoverageBuy ➝ Buy$82.00Low
5/12/2017Bank of AmericaInitiated CoverageBuy ➝ Buy$85.00High
5/10/2017Canaccord GenuityReiterated RatingBuy$110.00Medium
4/12/2017Canaccord GenuitySet Price TargetBuy$110.00High
4/3/2017JPMorgan Chase & Co.Reiterated RatingBuy$83.00High
3/21/2017Canaccord GenuityReiterated RatingBuy$110.00High
3/6/2017Canaccord GenuitySet Price TargetBuy$110.00N/A
2/23/2017Canaccord GenuitySet Price TargetBuy$110.00N/A
2/22/2017HC WainwrightDowngradeBuy ➝ Neutral$56.00 ➝ $76.00N/A
2/22/2017BMO Capital MarketsBoost Price TargetOutperform$68.00 ➝ $82.00N/A
2/14/2017Chardan CapitalUpgradeSell ➝ Neutral$60.00N/A
2/13/2017CowenReiterated RatingBuy$95.00N/A
2/13/2017BMO Capital MarketsSet Price TargetOutperform ➝ Buy$68.00N/A
1/11/2017JPMorgan Chase & Co.Reiterated RatingBuyN/A
12/15/2016JPMorgan Chase & Co.Reiterated RatingBuy$74.00N/A
12/14/2016Canaccord GenuitySet Price TargetBuy$110.00N/A
12/14/2016Raymond JamesUpgradeOutperform ➝ Strong-Buy$84.00N/A
12/14/2016UBS GroupUpgradeOutperform ➝ Strong-BuyN/A
12/6/2016Canaccord GenuityReiterated RatingBuy$110.00N/A
11/14/2016Stifel NicolausInitiated CoverageBuy$90.00N/A
11/3/2016CowenReiterated RatingBuyN/A
(Data available from 10/26/2016 forward)

News Sentiment Rating

0.31 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/29/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/28/2021
  • 3 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
7/28/2021
  • 2 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
8/27/2021
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/26/2021
  • 8 very positive mentions
  • 17 positive mentions
  • 6 negative mentions
  • 2 very negative mentions
10/26/2021

Current Sentiment

  • 8 very positive mentions
  • 17 positive mentions
  • 6 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Sage Therapeutics logo
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $41.43
Low: $40.75
High: $41.85

50 Day Range

MA: $44.67
Low: $40.26
High: $47.24

52 Week Range

Now: $41.43
Low: $39.77
High: $98.39

Volume

321,588 shs

Average Volume

622,506 shs

Market Capitalization

$2.44 billion

P/E Ratio

3.26

Dividend Yield

N/A

Beta

1.86

Frequently Asked Questions

What sell-side analysts currently cover shares of Sage Therapeutics?

The following sell-side analysts have issued reports on Sage Therapeutics in the last year: Bank of America Co., BMO Capital Markets, Canaccord Genuity, Citigroup Inc., Guggenheim, HC Wainwright, Jefferies Financial Group Inc., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Royal Bank of Canada, Smith Barney Citigroup, Stifel Nicolaus, SVB Leerink LLC, TheStreet, Truist, Wedbush, and William Blair.
View the latest analyst ratings for SAGE.

What is the current price target for Sage Therapeutics?

18 Wall Street analysts have set twelve-month price targets for Sage Therapeutics in the last year. Their average twelve-month price target is $78.00, suggesting a possible upside of 88.3%. Piper Sandler has the highest price target set, predicting SAGE will reach $100.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $50.00 for Sage Therapeutics in the next year.
View the latest price targets for SAGE.

What is the current consensus analyst rating for Sage Therapeutics?

Sage Therapeutics currently has 11 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SAGE, but not buy more shares or sell existing shares.
View the latest ratings for SAGE.

How do I contact Sage Therapeutics' investor relations team?

Sage Therapeutics' physical mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company's listed phone number is (617) 299-8380 and its investor relations email address is [email protected] The official website for Sage Therapeutics is www.sagerx.com.